Video series

View the first video of a series on healthcare professionals and their personal experience in treating with HEMLIBRA in patients with FVIII inhibitors. We look forward to sharing more HEMLIBRA stories in patients without FVIII inhibitors in the near future.

See below for additional data in patients with FVIII inhibitors.

Hear Dr. Callaghan’s experience treating with HEMLIBRA for patients with FVIII inhibitors

Dr. Michael Callaghan of the Children’s Hospital of Michigan shares one patient’s story.

As observed over 24 weeks (HAVEN 1) and 30 weeks (HAVEN 2) 

Sustained protection meant 0 treated bleeds for most patients 2

HEMLIBRA was studied in 2 pivotal, multicenter, open-label studies, HAVEN 1 and HAVEN 2, in adults, adolescents, and children with hemophilia A with factor VIII inhibitors. HEMLIBRA dosing: 3 mg/kg by subcutaneous injection once weekly (QW) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg by subcutaneous injection QW.



ABR=annualized bleed rate. ABR calculated with a negative binomial regression model, which accounts for different follow-up times. 15

BPAs=bypassing agents; CI=confidence interval; FVIII=factor VIII; IQR=interquartile range; QW=every week.

*Defined as bleeds treated with bypassing agents based on an adaptation of standard criteria defined by the International Society on Thrombosis and Haemostasis (ISTH). 15

Share Your Story

Reach out to your HEMLIBRA representative to share your experience in treating HEMLIBRA patients without FVIII inhibitors

Support for Your Patients

Find out about assistance for your eligible patients